RIBAVIRIN DOES NOT IMPACT HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS ON OMBITASVIR/ PARITAPREVIR /RITONAVIR AND DASABUVIR AT THE END OF 12-WEEK TREATMENT IN TREATMENT-NAIVE ADULTS WITH GENOTYPE 1A (GT1A) CHRONIC HEPATITIS C

被引：0

作者：

Liu, Y. ^{[1
]}

Bernstein, D. ^{[2
]}

Larsen, L. ^{[1
]}

Luo, Y. ^{[1
]}

Xie, Y. ^{[1
]}

Juday, T. ^{[1
]}

机构：

[1] AbbVie Inc, N Chicago, IL USA

[2] N Shore Univ Hosp, Manhasset, IL USA

来源：

VALUE IN HEALTH | 2015年 / 18卷 / 03期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PGI30

引用

页码：A227 / A227

页数：1

共 50 条

[1] OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR WITH RIBAVIRIN (RBV) HAS MINIMAL IMPACT ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) COMPARED WITH PLACEBO DURING 12-WEEK TREATMENT IN TREATMENT-NAIVE ADULTS WITH CHRONIC HEPATITIS C (CHC)
Liu, Y.
Larsen, L.
Zeuzem, S.
Coakley, E.
Baran, R.
Juday, T.
JOURNAL OF HEPATOLOGY, 2015, 62 : S668 - S668
[2] OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR WITH RIBAVIRIN (RBV) HAS MILD IMPACT ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) COMPARED WITH PLACEBO DURING 12-WEEK TREATMENT IN TREATMENT-EXPERIENCED ADULTS WITH CHRONIC HEPATITIS C (CHC)
Liu, Y.
Larsen, L.
Bourliere, M.
Baran, R.
Juday, T.
JOURNAL OF HEPATOLOGY, 2015, 62 : S661 - S661
[3] Better Work Productivity and Activity in Patients on Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin (3D+RBV or 3D) in Treatment-Naive Adults with Genotype 1(GT1) Chronic Hepatitis C
Liu, Yan
Luo, Yan
Liu, Xuan
Sullivan, Danielle
Juday, Timothy R.
Conway, Brian
HEPATOLOGY, 2015, 62 : 802A - 802A
[4] EFFECTIVENESS OF LEDIPASVIR/SOFOSBUVIR AND OMBITASVIR/PARITAPREVIR/RITONAVIR/DASABUVIR IN TREATMENT-NAIVE AND -EXPERIENCED US VETERANS WITH GENOTYPE 1 HEPATITIS C INFECTION
Fuchs, M.
Forte, V.
Tassone, D.
Owens, S.
Garcia, C.
Obolewicz, B.
Solomon, C.
Gilles, H.
Gavis, E.
Heuman, D.
JOURNAL OF HEPATOLOGY, 2016, 64 : S797 - S798
[5] Health-related quality of life (HRQOL) with albinterferon alfa-213 plus ribavirin in IFN treatment-naive patients with genotype 1 chronic hepatitis C
Pianko, S.
Yoshida, E.
Zeuzem, S.
Benhamou, Y.
Bain, V.
Pulkstenis, E.
McHutchison, J. G.
Subramanian, G. M.
JOURNAL OF HEPATOLOGY, 2008, 48 : S306 - S307
[6] Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection
Johnson, Scott J.
Parise, Helene
Virabhak, Suchin
Filipovic, Ivana
Samp, Jennifer C.
Misurski, Derek
JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (10) : 983 - 994
[7] Effect of ombitasvir/paritaprevir/ritonavir plus dasabuvir regimen on health-related quality of life for patients with hepatitis C
Saab, Sammy
Mehta, Darshan
Hudgens, Stacie
Grunow, Nathan
Bao, Yanjun
Pinsky, Brett
LIVER INTERNATIONAL, 2018, 38 (08) : 1377 - 1394
[8] Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection
Smith, Michael A.
Lim, Alice
DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 6083 - 6094
[9] Effectiveness of 8-and 12-Week Treatment with Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naive HCV Patients in a Real-Life Setting in Romania: the AMETHYST Study
Trifan, Anca
Stanciu, Carol
Iliescu, Laura
Sporea, Ioan
Baroiu, Liliana
Diculescu, Mircea
Luca, Mihaela-Catalina
Miftode, Egidia
Cijevschi, Cristina
Mihai, Catalina
Sparchez, Zeno-Adrian
Pojoga, Cristina
Streinu-Cercel, Adrian
Gheorghe, Liliana
JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2021, 30 (01) : 88 - 93
[10] Health-related quality of life (HRQOL) with albinterferon alfa-2b plus ribavirin in IFN Treatment-NaiVe patients with genotype 1 chronic hepatitis C
Pianko, Stephen
Yoshida, Eric M.
Zeuzem, Stefan
Benhamou, Yves
Bain, Vincent G.
Pulkstenis, Erik
McHutchison, John G.
Subramanian, Mani
GASTROENTEROLOGY, 2008, 134 (04) : A787 - A787

← 1 2 3 4 5 →